RT Journal Article
SR Electronic
T1 Chinese moyamoya disease study:cohort profile
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.20.23287508
DO 10.1101/2023.03.20.23287508
A1 Fang-Bin Hao
A1 Cong Han
A1 Gan Gao
A1 Si-meng Liu
A1 Min-jie Wang
A1 Ri-Miao Yang
A1 Zheng-Xing Zou
A1 Dan Yu
A1 Caihong Sun
A1 Qian Zhang
A1 Houdi Zhang
A1 Qing-Bao Guo
A1 Xiao-Peng Wang
A1 Xuxuan Shen
A1 Heguan Fu
A1 JingJie Li
A1 Zheng-shan Zhang
A1 Xiang-Yang Bao
A1 Jie Feng
A1 Bin Li
A1 Bin Ren
A1 Hui Wang
A1 Qian-Nan Wang
A1 Songtao Pei
A1 Bo Zhao
A1 Zhenglong Zou
A1 Yi-Qin Han
A1 Huaiyu Tong
A1 Zhenghui Sun
A1 Miao Liu
A1 Lian Duan
YR 2023
UL http://medrxiv.org/content/early/2023/03/22/2023.03.20.23287508.abstract
AB Background The etiology and natural course of moyamoya disease (MMD) remain unknown. This study evaluated the natural course and etiology of MMD using data from the Chinese MMD (C-MMD) cohort study.Methods The C-MMD cohort consisted of 6,167 patients with MMD treated at our center over the past 20 years. We analyzed the medical history and laboratory and imaging examination results of the patients at different stages of the disease to identify common features of MMD.Results The median age for symptom onset was 32 years. The age distribution was bimodal; the highest peak was between ages 35 and 45 years, with a smaller peak between ages 3 and 9 years. The female-to-male ratio was 1:1. The disease occurred mainly in the Han people and was rarely observed in minority nationalities. In our cohort, a transient ischemic attack was the most common initial clinical manifestation (46.3%); others included infarction (25.0%), hemorrhage (15.1%), and headache (7.9%).Conclusions The C-MMD cohort is currently one of the largest single-center MMD cohorts in the world. This study provides baseline data for future research on the etiology and natural course of MMD.Clinical Trial Registration This study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160).Funding StatementThis research was supported by the National Natural Science Foundation of China (Grant no: 82171280).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the General Hospital of the Chinese People's Liberation Army approved this study (No. KY-2022-9-69-1). This study has been registered in the Chinese Clinical trial registry (registration number: ChiCTR2200064160).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesC-MMD cohort members welcome and encourage collaboration to maximize the use of data and samples. The data is currently not freely available in the public domain owing to sensitive information in the study database. However, specific proposals for possible collaborations are welcome. Researchers interested in collaboration and further information are invited to contact the corresponding author by email at: duanlian307{at}sina.com (Duan lian).C-MMDChinese moyamoya diseaseDSADigital subtraction angiographyMRAMagnetic resonance angiographyMMDMoyamoya diseaseTIATransient ischemic attack